We work with innovators at the forefront of drug discovery to help transform bold ideas into life-changing therapies and technologies.
Whether you are biotech entrepreneur, academic scientist, or drug discovery innovator, our support is designed to reduce risk, build momentum, and accelerate your path to commercialisation.
We combine our team’s deep scientific expertise with state-of-the-art technology and a detailed understanding of patient and market needs to co-design and execute effective drug strategies.
From lab-based experimentation to industrial consultancy, we apply patient and market insights to determine the quickest, safest, and most effective way to develop new medicines.
We ask the right questions at the right time and validate your ideas through our expertise, data, insights, and technology to create a roadmap for commercial success.
We recognise that innovation journeys are complex, and every project is different. That is why we tailor our collaboration model to suit your goals, helping you advance with confidence, speed, and clarity. You can work with us through:
Lab-based discovery support
We can undertake cutting-edge laboratory work to generate decision-critical data and validate your concepts using the latest tools in in vitro biology, in vivo biology and biomarkers.
Strategic planning and expert consultancy
From target selection to first-in-human readiness, we offer tailored guidance to help you navigate the drug discovery process. We can develop robust strategies that safeguard your IP and maximise your commercial potential.
Flexible partnership models
We have various models to work in partnership with you, flexible to your needs:
As a not-for-profit national Life Sciences service, we reinvest our commercial revenue back into the drug discovery ecosystem. That means your progress fuels broader innovation.
Since our inception, we have:
Our team of 140+ scientists, strategists and technologists operate from Alderley Park and are united by one goal, to reshape drug discovery for patient benefit.
“We are focused on transforming great science into better treatments for patients. We share your ambition. Your success is our success.”
Professor Chris Molloy, Chief Executive Officer
From de-risking early-stage concepts to advancing preclinical assets, we are ready to help shape your next breakthrough.
Speak to us today and see how we can help make your next count.